Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

ZBIO

Zenas Biopharma Inc.

Oct 07 • 02:15PM ET

18.95

Dollar change +0.14
Percentage change 0.74	%

Healthcare • Biotechnology • USA • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	38.32M	Perf Week	12.00%
Market Cap	754.02M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	20.23M	Perf Month	-
Income	-	PEG	-	EPS next Q	-	Inst Own	10.05%	Short Float	0.00%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	158.43%	Short Ratio	0.00	Perf Half Y	-
Book/sh	-7.54	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.00M	Perf Year	-
Cash/sh	4.62	P/C	4.10	EPS next 5Y	-	ROE	-	52W Range	16.17 - 20.50	Perf YTD	4.41%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-7.56%	Beta	-
Dividend TTM	-	Quick Ratio	4.82	Sales past 5Y	-	Gross Margin	-	52W Low	17.19%	ATR (14)	1.69
Dividend Ex-Date	Dec 24, 2019	Current Ratio	4.82	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	-	Volatility	10.72% -
Employees	-	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-	Payout	-	Rel Volume	0.31	Prev Close	18.81
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	251.08K	Price	18.95
SMA20	4.97%	SMA50	4.97%	SMA200	4.97%	Trades		Volume	57,351	Change	0.74%

Sep-19-24 04:15PM	Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering (GlobeNewswire) +8.45%
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 10:37PM	Zenas BioPharma Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MOULDER LEON O JR	Chief Executive Officer	Sep 18 '24	Buy	17.91	10,000	179,100	1,662,039	Sep 20 06:34 PM
MOULDER LEON O JR	Chief Executive Officer	Sep 20 '24	Buy	18.45	5,000	92,270	1,672,039	Sep 20 06:34 PM
MOULDER LEON O JR	Chief Executive Officer	Sep 19 '24	Buy	17.89	5,000	89,450	1,667,039	Sep 20 06:34 PM
Enavate Sciences GP, LLC	10% Owner	Sep 16 '24	Buy	17.00	882,353	15,000,001	3,761,359	Sep 18 04:15 PM
Lu Hongbo	Director	Sep 13 '24	Buy	17.00	58,823	999,991	58,823	Sep 17 07:52 PM
ENRIGHT PATRICK G	Director	Sep 16 '24	Buy	17.00	440,000	7,480,000	774,530	Sep 16 08:57 PM
Nunn Jason Raleigh	Director	Sep 16 '24	Buy	17.00	882,352	14,999,984	1,946,564	Sep 16 08:54 PM
Fairmount Funds Management LLC	Director	Sep 16 '24	Buy	17.00	300,000	5,100,000	1,604,891	Sep 16 08:54 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	Sep 16 '24	Buy	17.00	2,235,294	37,999,998	1,946,564	Sep 16 08:51 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZBIO

Zenas Biopharma Inc.

Upgrade your FINVIZ experience